Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target

Area of Science:

• Virology
• Drug Discovery
• Structural Biology

Background:

• Drug-resistant strains of human immunodeficiency virus type 1 (HIV-1) impede effective long-term treatment for individuals with acquired immune deficiency syndrome (AIDS).
• Novel therapeutic strategies targeting structural viral components are essential to address the global AIDS pandemic.
• The HIV-1 reverse transcriptase (RT) dimer interface is a critical determinant of enzyme stability and function, presenting a novel target for anti-HIV-1 drug development.

Purpose of the Study:

• To review small molecule and peptide inhibitors that disrupt the formation of the active HIV-1 reverse transcriptase (RT) heterodimer.
• To discuss critical regions within the RT involved in dimerization that represent potential targets for chemotherapeutic intervention.

Main Methods:

• Review of existing literature on HIV-1 RT inhibitors, focusing on their impact on RT dimer stability and function.
• Analysis of studies investigating small molecules and peptides that interfere with RT heterodimer formation.
• Identification of key structural regions within RT essential for dimerization.

Main Results:

• Existing RT inhibitors can destabilize RT dimer formation, impairing polymerase function and serving as leads for new drug design.
• Potent nonnucleoside reverse transcriptase inhibitors (NNRTIs) may enhance RT subunit interaction, contributing to their inhibitory effects.
• Interface peptides demonstrate enzyme suppression by hindering active RT heterodimer formation.

Conclusions:

• The HIV-1 RT dimer interface is a viable and novel target for developing new anti-HIV-1 therapeutics.
• Small molecules and peptides that interfere with RT dimerization hold significant potential for combating HIV-1 infection.
• Further exploration of RT dimerization regions can guide the development of effective chemotherapeutic interventions against AIDS.